Bachem brings peptide API CMO offers to CPhI Japan
News | Bachem AG
MARCH 06, 2019
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG is will be returning to Asia’s premier pharma trade expo, CPhI Japan in Tokyo, with an expanded portfolio of CMO capabilities in peptide-based active pharmaceutical ingredients (APIs) and innovative selective glycosylation processes.
The Bachem display at Booth 2H-33 at Tokyo’s Big sight Exhibition Center will focus on its innovative portfolio of small molecule APIs and proprietary processes that harness its outstanding knowledge of peptide and carbohydrate chemistry, summed up in the Bachem offer ‘Pioneering Partner for Peptides’.
CMO for peptide APIs
The Bachem offer will be summarized by Dr. Satoshi Mashiko, Head of Business Development, for Tokyo-based Bachem K.K. in his presentation “Why Bachem is your peptide API CMO”, to be delivered on the afternoon of Day One of the conference sessions (1430 hrs, Room B).
Bachem’s award-winning single glycosylation process has enabled production scale chemical synthesis of Interferon β-1a, along with custom manufacturing, synthetic organic chemistry, generic peptidic and small molecule APIs and their impurities.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.
About CPhI Japan 2019
CPhI Japan is one of the family of high profile pharma trade shows created by UBM Live.
CPhI Japan 2019 is a three-day event opening March 18 at Tokyo’s Big Sight Exhibition Center. Apart from the main CPhI expo, there are four other zoned exhibitions: InnoPack, P-MEC (including LabWorld) for machinery and equipment, ICSE for outsourcing solutions, and BioPh for biotechnology.
The 2019 CPhI Japan show is expected to exceed previous attendance records, attracting more than 20,000 visitors from some 55 countries. The event is organized by UBM Live with further information at: www.cphi.com/japan/home/
Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107